Management of chronic hepatitis B in special populations: Immunosuppressed patients and chronic kidney disease

Fabrizio Fabrizi, Vivek Dixit, Piergiorgio Messa, Paul Martin

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Hepatitis B virus (HBV) infection remains an important cause of liver disease in the population with chronic kidney disease, including patients on long-term dialysis and renal transplant (RT) recipients. Diminished survival due to hepatitis B has been observed after RT. A thorough evaluation, including liver biopsy as well as assessment of serum markers of HBV replication (ie, hepatitis B e antigen and/or HBV DNA) is required before transplantation. Tolerance to interferon is poor both in dialysis patients and after renal transplant. Oral antiviral therapy now permits safe and potent antiviral treatment of HBV-related liver disease in chronic kidney disease patients with prevention of progressive liver disease. Preliminary evidence shows an improved survival of HBsAg positive renal allograft recipients on antiviral therapy. However, numerous issues concerning the treatment of hepatitis B in the population with chronic kidney disease remain unclear and further clinical trials are needed.

Original languageEnglish
Pages (from-to)269-276
Number of pages8
JournalCurrent Hepatitis Reports
Volume10
Issue number4
DOIs
Publication statusPublished - Dec 2011

Fingerprint

Chronic Hepatitis B
Chronic Renal Insufficiency
Hepatitis B virus
Antiviral Agents
Liver Diseases
Hepatitis B
Kidney
Population
Transplants
Hepatitis B e Antigens
Virus Diseases
Therapeutics
Hepatitis B Surface Antigens
Virus Replication
Interferons
Allografts
Renal Dialysis
Dialysis
Transplantation
Biomarkers

Keywords

  • Chronic kidney disease
  • Hepatitis B Virus
  • Immunosuppressive therapy
  • Kidney transplantation
  • Special populations
  • Survival

ASJC Scopus subject areas

  • Hepatology
  • Virology

Cite this

Management of chronic hepatitis B in special populations : Immunosuppressed patients and chronic kidney disease. / Fabrizi, Fabrizio; Dixit, Vivek; Messa, Piergiorgio; Martin, Paul.

In: Current Hepatitis Reports, Vol. 10, No. 4, 12.2011, p. 269-276.

Research output: Contribution to journalArticle

@article{acd7cb1a9de04f09b41b6dee0915baad,
title = "Management of chronic hepatitis B in special populations: Immunosuppressed patients and chronic kidney disease",
abstract = "Hepatitis B virus (HBV) infection remains an important cause of liver disease in the population with chronic kidney disease, including patients on long-term dialysis and renal transplant (RT) recipients. Diminished survival due to hepatitis B has been observed after RT. A thorough evaluation, including liver biopsy as well as assessment of serum markers of HBV replication (ie, hepatitis B e antigen and/or HBV DNA) is required before transplantation. Tolerance to interferon is poor both in dialysis patients and after renal transplant. Oral antiviral therapy now permits safe and potent antiviral treatment of HBV-related liver disease in chronic kidney disease patients with prevention of progressive liver disease. Preliminary evidence shows an improved survival of HBsAg positive renal allograft recipients on antiviral therapy. However, numerous issues concerning the treatment of hepatitis B in the population with chronic kidney disease remain unclear and further clinical trials are needed.",
keywords = "Chronic kidney disease, Hepatitis B Virus, Immunosuppressive therapy, Kidney transplantation, Special populations, Survival",
author = "Fabrizio Fabrizi and Vivek Dixit and Piergiorgio Messa and Paul Martin",
year = "2011",
month = "12",
doi = "10.1007/s11901-011-0116-0",
language = "English",
volume = "10",
pages = "269--276",
journal = "Current Hepatitis Reports",
issn = "1540-3416",
publisher = "Springer Publishing Company",
number = "4",

}

TY - JOUR

T1 - Management of chronic hepatitis B in special populations

T2 - Immunosuppressed patients and chronic kidney disease

AU - Fabrizi, Fabrizio

AU - Dixit, Vivek

AU - Messa, Piergiorgio

AU - Martin, Paul

PY - 2011/12

Y1 - 2011/12

N2 - Hepatitis B virus (HBV) infection remains an important cause of liver disease in the population with chronic kidney disease, including patients on long-term dialysis and renal transplant (RT) recipients. Diminished survival due to hepatitis B has been observed after RT. A thorough evaluation, including liver biopsy as well as assessment of serum markers of HBV replication (ie, hepatitis B e antigen and/or HBV DNA) is required before transplantation. Tolerance to interferon is poor both in dialysis patients and after renal transplant. Oral antiviral therapy now permits safe and potent antiviral treatment of HBV-related liver disease in chronic kidney disease patients with prevention of progressive liver disease. Preliminary evidence shows an improved survival of HBsAg positive renal allograft recipients on antiviral therapy. However, numerous issues concerning the treatment of hepatitis B in the population with chronic kidney disease remain unclear and further clinical trials are needed.

AB - Hepatitis B virus (HBV) infection remains an important cause of liver disease in the population with chronic kidney disease, including patients on long-term dialysis and renal transplant (RT) recipients. Diminished survival due to hepatitis B has been observed after RT. A thorough evaluation, including liver biopsy as well as assessment of serum markers of HBV replication (ie, hepatitis B e antigen and/or HBV DNA) is required before transplantation. Tolerance to interferon is poor both in dialysis patients and after renal transplant. Oral antiviral therapy now permits safe and potent antiviral treatment of HBV-related liver disease in chronic kidney disease patients with prevention of progressive liver disease. Preliminary evidence shows an improved survival of HBsAg positive renal allograft recipients on antiviral therapy. However, numerous issues concerning the treatment of hepatitis B in the population with chronic kidney disease remain unclear and further clinical trials are needed.

KW - Chronic kidney disease

KW - Hepatitis B Virus

KW - Immunosuppressive therapy

KW - Kidney transplantation

KW - Special populations

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=81355160499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81355160499&partnerID=8YFLogxK

U2 - 10.1007/s11901-011-0116-0

DO - 10.1007/s11901-011-0116-0

M3 - Article

AN - SCOPUS:81355160499

VL - 10

SP - 269

EP - 276

JO - Current Hepatitis Reports

JF - Current Hepatitis Reports

SN - 1540-3416

IS - 4

ER -